New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery

May 11, 2023
Category: Press Releases

98.9% of patients treated with Xoft remained recurrence-free at a median follow-up of 7.6 years, according to recent study published in Journal of Contemporary Brachytherapy

 

NASHUA, N.H., May 11, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling new long-term real-world research confirms Xoft Skin eBx is as safe and effective as Mohs surgery for the treatment of n... Continue reading

Tags: press releases

iCAD Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy (IORT) for Brain, Rectal, Head and Neck Tumor Treatment

April 05, 2022
Category: Press Releases

Multiple leading institutions leverage the versatility of Xoft electronic brachytherapy (eBx) to increasingly treat multiple cancers

 

 

NASHUA, N.H. – April 5, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that additional patients have been treated under the international multi-center GLIOX trial and cus... Continue reading

Tags: Press Releases

First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States

December 14, 2021
Category: Press Releases

Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor

 

Intriguing research supporting novel therapy approach recently published in peer-reviewed journal, Surgical Neurology International

 

 NA... Continue reading

Tags: press releases

iCAD’s Xoft Brain IORT Demonstrates Significant Improvement in Overall Survival in Recurrent Glioblastoma According to Comparative Study

August 31, 2021
Category: Press Releases

Patients treated with Xoft Brain IORT lived for a range of 4 to 54 months after treatment without recurrence, whereas patients in the control group had a recurrence within 2 to 10 months and lived for 2 to 22.5 months after treatment

 

NASHUA, N.H. – August 31, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, t... Continue reading

iCAD Announces Educational Webinar Featuring Leading Global Experts Discussing New Multidisciplinary Approach for Treating Brain Tumors, May 25

May 17, 2021
Category: Press Releases

Company sees positive momentum as research contributes to growing body of evidence supporting Xoft intraoperative radiotherapy (IORT) technology for brain cancer

 

NASHUA, N.H. – May 17, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced a virtual roundtable discussion will feature leading experts on brain cancer from around the globe sharing clinical updates on how... Continue reading

Tags: press releases

iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption

December 29, 2020
Category: Press Releases

International Multi-Center Study to Commence January 2021

University of Louisville’s Trial on IORT for Large Brain Lesion Treatments Accelerating

First European Patient Treated for Brain Metastasis with Xoft IORT System

 

NASHUA, N.H. – December 29, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the app... Continue reading

Tags: press releases

iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress

November 25, 2020
Category: Press Releases

Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types

 

NASHUA, N.H. – November 25, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that researchers from Miguel Servet University Hospital in Zaragoza, Spain, will present new data from three clinical studies supporting the efficacy of the expanded Xoft® Axxent® Electronic Brachytherapy (eBx... Continue reading

Tags: press releases

New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers

October 23, 2020
Category: Press Releases

iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer Tumors

 

NASHUA, N.H. – October 23, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase the expanded platform for the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at the American Society for Radiation Oncology... Continue reading

Tags: press releases

New Data Supports iCAD’s Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma

October 19, 2020
Category: Press Releases

New, Encouraging Results and Overall Patient Survival Numbers to be Presented at European Congress of Neurosurgery 

 

NASHUA, N.H. – October 19, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new, promising clinical results supporting the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the t... Continue reading

Tags: press releases

iCAD Responds to CMS’ Finalized Radiation Oncology Alternative Payment Model

September 20, 2020
Category: Press Releases

IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therapy reduced

 

NASHUA, N.H. – September 20, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, is providing additional comments following the Centers for Medicare & Medicaid Services’ (CMS) publication of a new Innovation Cen... Continue reading

Tags: press releases

iCAD Appoints Jeffrey Sirek as Senior Vice President and General Manager of Xoft

July 20, 2020
Category: Press Releases

NASHUA, N.H. – July 20, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Jeffrey Sirek was appointed as Senior Vice President and General Manager of Xoft.

 

“We are very pleased to add Mr. Sirek to our Company. He brings to the team a proven track record of high sales productivity, brand development, marketing success, an... Continue reading

Tags: press releases

iCAD Hosts Virtual Roundtable Event on Breast Cancer Surgery and Targeted Radiation During COVID-19

June 01, 2020
Category: Press Releases

 Leading breast cancer specialists to share best practices on leveraging the latest in cancer therapies to enhance patient care and minimize virus exposure


NASHUA, N.H. – June 1, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled “The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy,” on June 4, 2020 at 7 pm ET/4 pm... Continue reading

Tags: press releases

iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

May 13, 2020
Category: Press Releases

Promising clinical research supports Xoft brain IORT as a viable treatment option for glioblastoma multiforme that may extend patients’ lives

 

Overall survival benefit reached statistical significance in the IORT group with tumors less than or equal to 2.5 cm3 (p<0.05)


NASHUA, N.H. – May 13, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solut... Continue reading

Tags: press releases

First Brain Tumor Treated with Xoft IORT in the United States

February 11, 2020
Category: Press Releases

First U.S. procedure follows matched pair study indicating a promising improvement in overall survival

 

NASHUA, N.H. – February 11, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the first metastatic brain tumor was treated in the U.S. with intraoperative radiation therapy (IORT) using the Xoft® Axxe... Continue reading

Tags: press releases

iCAD Showcases Technology for Cancer “Discovery to Recovery” including ProFound AI Platform and Xoft System at Arab Health 2020 in Dubai

January 27, 2020
Category: Press Releases

iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthesis solution and a single-fraction therapy option for early-stage breast cancer

 

NASHUA, N.H. – January 27, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutio... Continue reading

Tags: press releases

iCAD Exhibiting New Updates and Enhanced Xoft Platform at ASTRO Including Single-Fraction IORT Solution for the Treatment of Early-Stage Breast Cancer

September 16, 2019
Category: Press Releases

Enhanced x-ray source technology and full suite of Xoft eBx applicators to be showcased, including those for emerging applications in prostate, brain, and rectal cancers

 

NASHUA, N.H. and CHICAGO – September 16, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase its latest advancements for the Xoft® Axxent® Electroni... Continue reading

Tags: press releases

iCAD Appoints R. Scott Areglado As Chief Financial Officer

May 06, 2019
Category: Press Releases

NASHUA, N.H. -- May 6, 2019 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today appointed R. Scott Areglado as Chief Financial Officer.  Mr. Areglado has been serving as interim Chief Financial Officer since December 2018, and previously held the role of Corporate Controller at iCAD since May 2011.

 

Continue reading

Tags: press releases

iCAD Wins Three-System Public Bid with Leading Cancer Organization in Spain, Expanding European Access to Innovative Cancer Treatments with the Xoft System

April 15, 2019
Category: Press Releases

Two additional Spanish centers announce adoption of the Xoft System, totaling seven installations across four major regions in Spain

 

Internationally-recognized institutions strengthen portfolio of comprehensive cancer care solutions with iCAD’s state-of-the-art electronic brachytherapy technology

 

Continue reading

Tags: press releases

iCAD Appoints Stacey Stevens as President

March 28, 2019
Category: Press Releases

Appointment establishes executive infrastructure to enhance strategic and operational momentum and capitalize on significant growth opportunities

 

Announcement follows pivotal FDA clearance and successful U.S. commercial launch of ProFound AI™ for digital breast tomosynthesis along... Continue reading

Tags: press releases

Long-Term Study of 1,000 Tumors Demonstrates Effectiveness of iCAD's Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment

January 07, 2019
Category: Press Releases

Prospective trial shows that intraoperative radiation therapy (IORT) is a clinically effective, faster and easier alternative to whole breast radiation therapy following breast-conserving surgery for selected low-risk patients at a median follow-up of 36 months


NASHUA, N.H., (January 7, 2019) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the results of a long-term study conducted at Hoag Memorial Hospital Pre... Continue reading

Tags: Press Releases

© Xoft, a subsidiary of iCAD, Inc. All rights reserved. Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc.  Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.